Faron, etusivu

Tiedotteet ja julkaisut

Faron Pharmaceuticals julkistaa tiedotteensa englannin kielellä.

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Shareholder announcement Regulatory

Faron Announces First Patient Enrolled in BEXAR Investigator-Initiated Trial

Faron Pharmaceuticals Ltd: Half-year financial results 1 January – 30 June 2026

Regulatory

Faron Pharmaceuticals Ltd: Notice of Half-Year Financial Results

Regulatory

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Shareholder announcement Regulatory

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Shareholder announcement Regulatory

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds

Regulatory

Inside Information: Faron announces encouraging first overall survival data from frontline higher-risk (HR) MDS patients in the BEXMAB phase 1/2 trial

Regulatory

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Shareholder announcement Regulatory

Faron Provides Update on Investigator-Initiated Trial Portfolio for Bexmarilimab

Next
Siirry takaisin sivun alkuun